Table 3.
Defined daily doses and prescribed daily doses of monoclonal antibodies prescribed to the study population.
| Monoclonal antibody | ATC codes | DDD (in mg, parenteral route) | PDD (in mg parenteral route) | PDD/DDD ratio |
|---|---|---|---|---|
| Evolocumab | C10AX13 | 10.0 | 10.0 | 1.0 |
| Palivizumab | J06BD01 | — | 2.93 | — |
| Dupilumab | D11AH05 | 21.4 | 21.4 | 1.0 |
| Denosumab | M05BX04 | 0.33 | 0.33 | 1.0 |
| Romosozumab | M05BX06 | 7.0 | 7.0 | 1.0 |
| Secukinumab | L04AC10 | 10.0 | 10.0 | 1.0 |
| Omalizumab | R03DX05 | 16.0 | 21.4 | 1.33 |
| Adalimumab | L04AB04 | 2.90 | 2.85 | 0.98 |
| Erenumab | N02CD01 | 2.50 | 2.50 | 1.0 |
| Ustekinumab | L04AC05 | 0.54 | 0.50 | 0.92 |
| Mepolizumab | R03DX09 | 3.60 | 3.60 | 1.0 |
DDD: defined daily dose; PDD: prescribed daily dose; ATC: anatomical therapeutic chemical classification.